Bicycle Therapeutics (BCYC) Common Equity (2018 - 2025)
Historic Common Equity for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $618.5 million.
- Bicycle Therapeutics' Common Equity fell 2557.7% to $618.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.5 million, marking a year-over-year decrease of 2557.7%. This contributed to the annual value of $793.1 million for FY2024, which is 11380.2% up from last year.
- As of Q3 2025, Bicycle Therapeutics' Common Equity stood at $618.5 million, which was down 2557.7% from $668.9 million recorded in Q2 2025.
- Bicycle Therapeutics' Common Equity's 5-year high stood at $873.8 million during Q2 2024, with a 5-year trough of $142.0 million in Q2 2021.
- In the last 5 years, Bicycle Therapeutics' Common Equity had a median value of $346.3 million in 2021 and averaged $428.2 million.
- In the last 5 years, Bicycle Therapeutics' Common Equity plummeted by 2931.84% in 2023 and then soared by 29701.27% in 2024.
- Over the past 5 years, Bicycle Therapeutics' Common Equity (Quarter) stood at $346.3 million in 2021, then decreased by 21.8% to $270.8 million in 2022, then soared by 36.98% to $370.9 million in 2023, then surged by 113.8% to $793.1 million in 2024, then fell by 22.01% to $618.5 million in 2025.
- Its Common Equity was $618.5 million in Q3 2025, compared to $668.9 million in Q2 2025 and $740.3 million in Q1 2025.